ACKERMANN CHRISTINA 4
4 · Verona Pharma plc · Filed May 16, 2025
Insider Transaction Report
Form 4
ACKERMANN CHRISTINA
Director
Transactions
- Exercise/Conversion
Share Options (Right to Buy)
2025-05-14−40,000→ 200,000 totalExercise: $1.93Exp: 2034-04-28→ Ordinary Shares (40,000 underlying) - Exercise/Conversion
Ordinary Shares
2025-05-14$1.93/sh+40,000$77,352→ 81,880 total - Sale
Ordinary Shares
2025-05-14$8.44/sh−40,000$337,600→ 41,880 total
Footnotes (6)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on February 12, 2025.
- [F3]The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.3894 to $8.5688 per Ordinary Share, inclusive (or $67.115 to $68.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]Consists of 41,880 Ordinary Shares represented by 5,235 ADSs.
- [F5]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
- [F6]The option is fully vested.